Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 189 Total
CGTL - Creative Global Technology Holdings Ltd - Stock Price Chart
TickerCGTL [NASD]
CompanyCreative Global Technology Holdings Ltd
CountryHong Kong
IndustrySpecialty Retail
Market Cap32.37MEPS (ttm)0.03
P/E58.98EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S7.10EPS next 5Y-
P/B18.68EPS Q/Q124.66%
Dividend-Sales Q/Q-32.55%
Insider Own93.29%Inst Own0.56%
Insider Trans0.00%Inst Trans0.12%
Short Float0.95%Earnings-
Analyst Recom-Target Price-
Avg Volume231.64K52W Range2.80 - 10.59
Creative Global Technology Holdings Ltd. engages in sourcing and reselling recycled consumer electronic devices through its subsidiary. The company was founded in 2016 and is headquartered in Hong Kong.
COEP - Coeptis Therapeutics Holdings Inc - Stock Price Chart
TickerCOEP [NASD]
CompanyCoeptis Therapeutics Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap26.29MEPS (ttm)-5.65
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-322.46%
P/S-EPS next 5Y-
P/B3.08EPS Q/Q33.06%
Dividend-Sales Q/Q-
Insider Own14.11%Inst Own0.32%
Insider Trans0.00%Inst Trans-21.77%
Short Float1.83%Earnings-
Analyst Recom1.00Target Price80.00
Avg Volume60.09K52W Range2.31 - 13.70
Apr-25-25 08:33AM Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement (GlobeNewswire) -38.25%
Apr-17-25 08:38AM COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology (GlobeNewswire) +7.82%
Apr-15-25 08:33AM NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives (Business Wire)
Mar-11-25 08:34AM Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline (GlobeNewswire)
Mar-07-25 08:37AM COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan (GlobeNewswire)
Mar-06-25 08:00AM NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan (Business Wire) -5.09%
Feb-20-25 09:00AM COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network (GlobeNewswire) -16.44%
07:27AM COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-19-25 04:00PM COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-13-25 08:39AM COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups (GlobeNewswire)
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
SMMT - Summit Therapeutics Inc - Stock Price Chart
TickerSMMT [NASD, RUT]
CompanySummit Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap17.31BEPS (ttm)-0.31
P/E-EPS this Y-37.58%
Forward P/E-EPS next Y-40.14%
PEG-EPS past 5Y-10.52%
P/S-EPS next 5Y-28.82%
P/B44.52EPS Q/Q-59.00%
Dividend-Sales Q/Q-
Insider Own84.93%Inst Own12.61%
Insider Trans0.00%Inst Trans9.99%
Short Float21.38%EarningsMay 01/a
Analyst Recom1.00Target Price36.88
Avg Volume3.16M52W Range2.10 - 36.91
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
TIL - Instil Bio Inc - Stock Price Chart
TickerTIL [NASD]
CompanyInstil Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap83.82MEPS (ttm)-11.39
P/E-EPS this Y1.45%
Forward P/E-EPS next Y-30.91%
PEG-EPS past 5Y-62.10%
P/S-EPS next 5Y11.18%
P/B0.49EPS Q/Q8.28%
Dividend-Sales Q/Q-
Insider Own49.08%Inst Own36.62%
Insider Trans0.00%Inst Trans-7.73%
Short Float16.92%EarningsMar 04/b
Analyst Recom1.75Target Price113.67
Avg Volume88.96K52W Range9.62 - 92.00
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
SAIA - Saia Inc - Stock Price Chart
TickerSAIA [NASD]
CompanySaia Inc
CountryUSA
IndustryTrucking
Market Cap6.54BEPS (ttm)13.51
P/E18.18EPS this Y-5.92%
Forward P/E15.68EPS next Y23.22%
PEG2.24EPS past 5Y25.72%
P/S2.04EPS next 5Y8.11%
P/B2.82EPS Q/Q-14.79%
Dividend-Sales Q/Q5.04%
Insider Own0.30%Inst Own113.15%
Insider Trans-18.24%Inst Trans2.90%
Short Float7.02%EarningsApr 25/b
Analyst Recom1.86Target Price383.47
Avg Volume569.07K52W Range287.50 - 624.55
Apr-25-25Upgrade Morgan Stanley Underweight → Equal-Weight
Apr-25-25Downgrade BMO Capital Markets Outperform → Market Perform $455 → $285
Saia, Inc. operates as a transportation company. It provides regional and interregional less-than-truckload (LTL) services. The firm offers full value coverage, logistics services, distribution and consolidation, trade show, customs clearance, retail delivery, cross border shipping to Mexico and Canada, and offshore shipping to Alaska, Hawaii and Puerto Rico. The company was founded by Louis Saia, Sr. in 1924 and is headquartered in Johns Creek, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAMU RAYMOND RExec. VP & Chief Customer Off.Feb 24 '25Option Exercise250.621,980496,2287,882Feb 26 04:07 PM
RAMU RAYMOND RExec. VP & Chief Customer Off.Feb 24 '25Sale415.801,980823,2925,902Feb 26 04:07 PM
RAYMOND R. RAMUOfficerFeb 24 '25Proposed Sale415.801,980823,292Feb 24 04:13 PM
Batteh Matthew JChief Financial OfficerFeb 18 '25Sale500.09700350,0643,326Feb 20 05:03 PM
Benton Kelly WVP & CAOFeb 18 '25Option Exercise277.86460127,8164,747Feb 20 05:03 PM
STRO - Sutro Biopharma Inc - Stock Price Chart
TickerSTRO [NASD, RUT]
CompanySutro Biopharma Inc
CountryUSA
IndustryBiotechnology
Market Cap76.14MEPS (ttm)-3.01
P/E-EPS this Y30.93%
Forward P/E-EPS next Y50.11%
PEG-EPS past 5Y-4.05%
P/S1.23EPS next 5Y32.32%
P/B1.67EPS Q/Q-272.39%
Dividend-Sales Q/Q-86.98%
Insider Own10.10%Inst Own72.75%
Insider Trans0.00%Inst Trans10.53%
Short Float7.07%EarningsMar 13/a
Analyst Recom2.36Target Price5.12
Avg Volume1.66M52W Range0.52 - 5.17
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Srinivasan VenkateshCHIEF TECH OP OFFICERApr 11 '25Option Exercise0.0021,250059,683Apr 15 04:09 PM
NEWELL WILLIAM JCEOMar 05 '25Option Exercise0.0018,7500299,239Mar 07 04:14 PM
FITZPATRICK LINDA ACHIEF PEOPLE & COMM. OFFICERMar 05 '25Option Exercise0.008,750099,027Mar 07 04:12 PM
ALBINI EDWARD CCFO AND SECRETARYMar 05 '25Option Exercise0.008,7500135,675Mar 07 04:11 PM
FITZPATRICK LINDA ACHIEF PEOPLE & COMM. OFFICERMar 04 '25Option Exercise0.009,125094,025Mar 06 04:12 PM
AZUL - Azul S.A. ADR - Stock Price Chart
TickerAZUL [NYSE]
CompanyAzul S.A. ADR
CountryBrazil
IndustryAirlines
Market Cap119.45MEPS (ttm)-14.47
P/E-EPS this Y83.29%
Forward P/E9.87EPS next Y125.61%
PEG-EPS past 5Y-22.27%
P/S0.03EPS next 5Y-
P/B-EPS Q/Q-6985.33%
Dividend-Sales Q/Q-4.03%
Insider Own-Inst Own9.14%
Insider Trans-Inst Trans-
Short Float7.27%EarningsFeb 24/b
Analyst Recom2.69Target Price3.57
Avg Volume1.55M52W Range1.04 - 6.64
Azul SA is a holding company, which engages in the provision of airline passenger and cargo services. The firm's service features include passenger seat selection, leather seats, individual entertainment screens with free live television at every seat in all E-Jets, extensive legroom with a pitch of 30 inches or more, complimentary beverage and snack services and free bus service to key airports. The company was founded by David Neeleman on January 03, 2008 and is headquartered in Barueri, Brazil.
VYNE - VYNE Therapeutics Inc - Stock Price Chart
TickerVYNE [NASD]
CompanyVYNE Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap21.75MEPS (ttm)-0.93
P/E-EPS this Y-32.78%
Forward P/E-EPS next Y16.19%
PEG-EPS past 5Y65.87%
P/S43.49EPS next 5Y4.50%
P/B0.41EPS Q/Q-41.60%
Dividend-Sales Q/Q10.53%
Insider Own16.66%Inst Own47.99%
Insider Trans0.60%Inst Trans8.47%
Short Float1.07%EarningsMar 06/b
Analyst Recom1.00Target Price6.38
Avg Volume127.57K52W Range1.44 - 4.30
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEPORE PATRICK GDirectorJan 15 '25Buy2.9215,00043,80051,472Jan 16 06:06 PM
LEXX - Lexaria Bioscience Corp - Stock Price Chart
TickerLEXX [NASD]
CompanyLexaria Bioscience Corp
CountryCanada
IndustryBiotechnology
Market Cap23.71MEPS (ttm)-0.58
P/E-EPS this Y-31.21%
Forward P/E-EPS next Y13.51%
PEG-EPS past 5Y21.61%
P/S44.73EPS next 5Y-18.14%
P/B3.30EPS Q/Q-156.88%
Dividend-Sales Q/Q20.00%
Insider Own7.31%Inst Own8.31%
Insider Trans4.05%Inst Trans-30.94%
Short Float4.18%EarningsJan 15
Analyst Recom1.00Target Price7.00
Avg Volume96.54K52W Range1.15 - 4.44
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHRISTOPHER RICHARDChief Executive OfficerDec 03 '24Buy2.4727,17267,17550,000Dec 03 02:03 PM
CHRISTOPHER RICHARDChief Executive OfficerDec 02 '24Buy2.2422,82851,21722,828Dec 03 02:03 PM
TURKEL CATHERINE C.DirectorAug 12 '24Buy3.131,6005,0083,100Aug 13 10:55 AM
Carle VanessaSecretaryJul 31 '24Sale4.002,56710,2680Aug 01 12:25 PM
Carle VanessaSecretaryMay 14 '24Option Exercise1.152,5002,8752,567May 15 05:37 PM
CERO - CERo Therapeutics Holdings Inc - Stock Price Chart
TickerCERO [NASD]
CompanyCERo Therapeutics Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap4.98MEPS (ttm)-38.99
P/E-EPS this Y59.83%
Forward P/E-EPS next Y88.20%
PEG-EPS past 5Y-
P/S-EPS next 5Y62.86%
P/B-EPS Q/Q106.14%
Dividend-Sales Q/Q-
Insider Own31.95%Inst Own4.62%
Insider Trans-88.23%Inst Trans5.92%
Short Float8.98%EarningsFeb 26
Analyst Recom1.00Target Price11.00
Avg Volume1.83M52W Range0.53 - 171.00
Apr-25-25 08:15AM CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (GlobeNewswire) -19.81%
Apr-24-25 08:15AM CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +38.85%
Apr-22-25 08:15AM CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing (GlobeNewswire) +18.70%
Apr-10-25 08:15AM CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 (GlobeNewswire) -7.89%
Apr-09-25 08:15AM CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +18.58%
Mar-31-25 08:15AM CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors (GlobeNewswire)
Mar-27-25 08:15AM CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing (GlobeNewswire) -9.51%
Mar-19-25 08:15AM CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services (GlobeNewswire)
Mar-13-25 08:15AM CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting (GlobeNewswire) -29.40%
Mar-06-25 08:15AM CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays (GlobeNewswire)
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ATWOOD BRIAN GDirectorMar 31 '25Option Exercise0.00294,46029490,534Apr 04 07:12 PM
YK Bioventures Opportunities G10% OwnerDec 13 '24Sale0.062,998,908179,93413,005,169Dec 13 06:41 PM
YK Bioventures Opportunities G10% OwnerDec 12 '24Sale0.071,614,541113,01816,004,077Dec 13 06:41 PM
YK Bioventures Opportunities G10% OwnerDec 11 '24Sale0.081,343,801107,50417,618,618Dec 13 06:41 PM
YK Bioventures Opportunities G10% OwnerDec 06 '24Sale0.121,236,874148,42521,383,909Dec 10 08:44 PM
1234561019